Skip to Main Content

We have a new app!

Take the Access library with you wherever you go—easy access to books, videos, images, podcasts, personalized features, and more.

Download the Access App here: iOS and Android. Learn more here!

INTRODUCTION

SUMMARY

Acute lymphoblastic leukemia (ALL) is a malignant disorder that originates in a single B- or T-lymphocyte progenitor. Proliferation and accumulation of clonal blast cells in the marrow result in suppression of hematopoiesis and, thereafter, anemia, thrombocytopenia, and neutropenia. Lymphoblasts can accumulate in various extramedullary sites, especially the meninges, gonads, thymus, liver, spleen, and lymph nodes. The disease is most common in children but occurs in individuals of any age. ALL has many subtypes and can be classified by immunologic, cytogenetic, and molecular genetic methods. These methods identify clinically important, biologic subtypes requiring treatment approaches that differ in their use of specific drugs or drug combinations, dosages of drug, or duration of treatment required to achieve optimal results. For example, cases of childhood ALL having a hyperdiploid karyotype respond well to extended treatment with methotrexate and mercaptopurine, whereas adults whose leukemic cells contain the Philadelphia chromosome and BCR-ABL1 fusion benefit from treatment that includes a tyrosine kinase inhibitor and transplantation of allogeneic hematopoietic stem cells. The lesser rate of therapeutic success in adult ALL is partly related to a high frequency of cases having unfavorable genetic abnormalities and partly related to poor tolerance for intensive treatment. Nearly 90% of children and 40% of adults can expect long-term, leukemia-free survival—and probable cure—with contemporary treatment. Novel immunotherapeutic approaches are under development. Currently, emphasis is placed not only on improving the cure rate but also on improving quality of life by preventing acute and late treatment–related complications, such as second malignancies, cardiotoxicity, and endocrinopathy.

Acronyms and Abbreviations

ALL, acute lymphoblastic leukemia; ara-G, 9-beta-D-arabinofuranosylguanine; ARID5B, AT-rich interactive domain 5b; ATM, ataxia-telangiectasia mutated gene; AYA, adolescents and young adults; BiTE, bispecific T-cell engaging;CAR, chimeric antigen receptor; CD, cluster of differentiation; CNAs, copy number abnormalities; CNS, central nervous system; CSF, cerebrospinal fluid; EFS, event-free survival; FISH, fluorescence in situ hybridization; HLA, human leukocyte antigen; hyper-CVAD, cyclophosphamide, vincristine, Adriamycin, dexamethasone; MRI, magnetic resonance imaging; NAD(P)H, nicotinamide adenine dinucleotide phosphate; PCR, polymerase chain reaction; RT-PCR, reverse transcriptase polymerase chain reaction; SEER, Surveillance, Epidemiology, and End Results; SNP, single nucleotide polymorphism; TPMT, thiopurine S-methyltransferase.

DEFINITION AND HISTORY

Acute lymphoblastic leukemia (ALL) is a neoplastic disease that results from multistep somatic mutations in a single lymphoid progenitor cell at one of several discrete stages of development. The immunophenotype of leukemic cells at diagnosis reflects the level of differentiation achieved by the dominant clone. The clonal origin of ALL has been established by cytogenetic analysis, by analysis of restriction fragments in female patients who are heterozygous for polymorphic X chromosome–linked genes, and by analysis of rearrangements of T-cell receptor or immunoglobulin genes. Leukemic cells divide more slowly and require more time to synthesize DNA than do normal hematopoietic counterparts. However, leukemic cells accumulate relentlessly because of their altered response to growth and death signals.1,2 They compete successfully with normal hematopoietic cells, resulting in anemia, thrombocytopenia, and ...

Pop-up div Successfully Displayed

This div only appears when the trigger link is hovered over. Otherwise it is hidden from view.